Philadelphia and Boston – September 24, 2026 -- Minaris, a global cell and gene therapy CDMO, has partnered with synthetic biology firm Asimov to integrate proprietary OXGENE viral vector technology into Asimov's AAV Edge producer cell lines, targeting higher manufacturing titers and improved product quality for adeno-associated virus (AAV) gene therapies.
Stable production systems aim to replace costly transient manufacturing
Most AAV programs currently rely on transient production, requiring multiple GMP plasmids to be transfected for every batch. This method drives up costs, limits scalability, and can produce inconsistent product quality. Stable production systems have historically been difficult to develop due to the complexity and interdependency of viral genetics involved.
Asimov's AAV Edge system targets high-titer, clonal cell lines
Asimov's AAV Edge Stable Producer System uses genetic design tools to engineer high-titer, clonal producer cell lines, addressing one of the industry's persistent bioproduction bottlenecks. Under the new agreement, Asimov gains the ability to incorporate Minaris' OXGENE technology into its cell line design toolkit.
"Stable producer cell lines are a key technology to enable AAV gene therapies at scale, and we are excited to partner with Minaris to unlock a new level of performance for our AAV Edge system,